Want to see CERT full AI Analyst Report?
CERT Stock Chart & Stats
$6.22
-$0.37(-3.29%)
At close: 4:00 PM EST
$6.22
-$0.37(-3.29%)
Day’s Range― - ―
52-Week Range$4.45 - $13.88
Previous CloseN/A
Volume176.64K
Average Volume (3M)4.51M
Market Cap
$1.08B
Enterprise Value$1.05K
Total Cash (Recent Filing)$149.48M
Total Debt (Recent Filing)$300.26M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 04, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding155,564,600
10 Day Avg. Volume3,668,895
30 Day Avg. Volume4,507,155
Financial Highlights & Ratios
PEG Ratio10.16
Price to Book (P/B)1.33
Price to Sales (P/S)3.37
P/FCF Ratio14.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.79Price Target Upside25.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.38
Revenue Forecast (FY)$398.74M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage (≈0.01 debt/equity) and a ~$1.0B equity base give Certara durable financial flexibility. This supports continued R&D, product investment, share repurchases and M&A optionality while reducing solvency risk during industry cycles, sustaining strategic initiatives over months.
Recurring Software Revenue And RetentionHigh net retention (106%) and a majority of software revenue being ratable/subscription (57%) create predictable, recurring cash flows. That recurring mix improves revenue visibility, supports long-term margin expansion opportunities, and underpins higher-quality bookings and investment in platform development over multiple quarters.
Regulatory Acceptance And AI/product MomentumRegulatory qualifications (EMA Simcyp, PBPK accepted) plus an AI-native team and partnerships with NVIDIA/Altasciences strengthen Certara's technological moat. Regulatory validation and strategic alliances boost product credibility and scalability, supporting durable demand from pharma and regulators across drug development cycles.
Bears Say
Persistent GAAP LossesOngoing GAAP losses and declining adjusted income weaken returns on capital and limit internal funding capacity for growth initiatives. Persistent net losses create pressure on long-term profitability metrics, complicate reinvestment pacing and could constrain strategic options if cash generation weakens further.
Services Revenue And Bookings WeaknessServices are a large part of revenue and their declining revenue and bookings signal structural go-to-market or demand issues. Sustained services softness can depress overall growth, reduce cross-sell economics into software, and limit margin resilience given services' lower scalability versus subscription software.
Transition And Execution Risk From Reorg/divestiture And Leadership ChangeDivesting regulatory/medical-writing assets, reorganizing into new operating units and an interim CFO appointment raise near-term execution risk. Such structural changes can disrupt sales motion, delay backlog conversion and complicate integration of AI/product initiatives, affecting performance until new structures embed.
Certara News
CERT FAQ
What was Certara, Inc.’s price range in the past 12 months?
Certara, Inc. lowest stock price was $4.45 and its highest was $13.88 in the past 12 months.
What is Certara, Inc.’s market cap?
Certara, Inc.’s market cap is $1.08B.
When is Certara, Inc.’s upcoming earnings report date?
Certara, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 14 days.
How were Certara, Inc.’s earnings last quarter?
Certara, Inc. released its earnings results on May 11, 2026. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.106 by -$0.016.
Is Certara, Inc. overvalued?
According to Wall Street analysts Certara, Inc.’s price is currently Undervalued.
Does Certara, Inc. pay dividends?
Certara, Inc. does not currently pay dividends.
What is Certara, Inc.’s EPS estimate?
Certara, Inc.’s EPS estimate is 0.09.
How many shares outstanding does Certara, Inc. have?
Certara, Inc. has 155,564,600 shares outstanding.
What happened to Certara, Inc.’s price movement after its last earnings report?
Certara, Inc. reported an EPS of $0.09 in its last earnings report, missing expectations of $0.106. Following the earnings report the stock price went down -18.7%.
Which hedge fund is a major shareholder of Certara, Inc.?
Currently, no hedge funds are holding shares in CERT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Certara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.79 (25.17% Upside)
$7.79 (25.17% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 133.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.88%
Trailing 12-Months
Company Description
Certara, Inc.
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
CERT Stock 12 Month Forecast
Average Price Target
$7.79
▲(25.17% Upside)
Technical Analysis
Omnicell
―
Health Catalyst
―
Schrodinger
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
2.52% Insiders
17.69% Mutual Funds
5.82% Other Institutional Investors
54.49% Public Companies and
Individual Investors